Add BrightSurf on Google Email

Mass General Brigham researchers find too much sitting hurts the heart

A new study by Mass General Brigham researchers found that excessive sedentary behavior increases the risk of heart failure and cardiovascular death. Even among individuals who meet guideline levels of moderate-to-vigorous physical activity, sitting for extended periods can still pose significant health risks. The study's findings sugg...

SourceMass General Brigham·JournalJournal of the American College of Cardiology·TypeObservational study·DateNov 15, 2024

Frequent emergency care during pregnancy could signal greater risk for severe maternal morbidity

A new study found that pregnant people in Massachusetts who made multiple unscheduled hospital visits during pregnancy were more likely to experience severe maternal morbidity. The study revealed that nearly half of these patients visited multiple hospitals, leading to inconsistent treatment and poor maternal outcomes.

SourceBoston University School of Public Health·JournalJAMA Network Open·TypeObservational study·DateNov 14, 2024

While more is better, even moderate amounts of exercise may reduce risk for common heart condition

A new study found that even moderate amounts of exercise can reduce the risk of atrial fibrillation, a common heart condition. The research, led by NYU Langone Health, used data from over 6,000 participants and showed that those with higher physical activity levels had a lower risk of developing the condition.

Transcriptomics-based study on the mechanism of heart failure amelioration by water decoction and water-soluble alkaloids of Fuzi

Researchers investigated the molecular mechanism of Fuzi's cardioprotective effects on heart failure. Fuzi water decoction and alkaloids were found to regulate apoptosis, proliferation, and anti-fibrosis in heart failure models, with ABC transporters potentially being a key pathway for their action.

SourceXia & He Publishing Inc.·JournalFuture Integrative Medicine·DateOct 29, 2024

Heart failure mortality declining in Sweden

A new study from Karolinska Institutet reveals a decline in heart failure mortality in Sweden over the last 20 years. Despite improvements, the prognosis for heart failure patients remains concerning, with 25% of those diagnosed in 2022 dying within a year.

SourceKarolinska Institutet·JournalEuropean Journal of Heart Failure·DateOct 28, 2024

UCLA researchers engineer experimental drug for preventing heart failure after heart attacks

Scientists at UCLA have engineered an experimental therapy that shows promise in enhancing heart repair following a heart attack, preventing the onset of heart failure. The new single-dose therapy targets the protein ENPP1, which is responsible for increasing inflammation and scar tissue formation.

CRF® announces 2024 SET-10 Rankings

The Cardiovascular Research Foundation recognizes 29 leading institutions for their contributions to groundbreaking research advancing interventional cardiovascular medicine. The 2024 SET-10 rankings celebrate institutions making significant impacts across various categories, including basic science and clinical research.

New therapeutic target for cardiac arrhythmias emerges

A new study identifies phosphatidylinositol 4,5-bisphosphate as a key regulator of the SK2 channel, which plays a critical role in cardiac ion channels and heart rhythm. The research provides critical translational insights into possible mechanisms of cardiac arrhythmias in heart failure.

SourceUniversity of Arizona Health Sciences·JournalProceedings of the National Academy of Sciences·TypeComputational simulation/modeling·DateOct 4, 2024

Heart transplant patients from socioeconomically deprived areas face higher risk for postoperative complications, earlier death than others

Researchers found that heart transplant recipients from most deprived areas had a higher risk of dying within five years and experiencing organ failure compared to those from less deprived areas. Treatment at high-quality hospitals did not translate into better outcomes.

SourceUniversity of California - Los Angeles Health Sciences·JournalThe Journal of Heart and Lung Transplantation·TypeData/statistical analysis·DateSep 30, 2024

Estimated long-term benefits of finerenone in heart failure

Long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone is estimated to extend event-free survival by up to 3 years among people with heart failure. The FINEARTS-HF randomized clinical trial found this benefit in patients with mildly reduced or preserved ejection fraction.

SourceJAMA Network·JournalJAMA Cardiology·DateSep 27, 2024

Absolute and functional iron deficiency in the US

A significant proportion of American adults suffer from absolute and functional iron deficiency, which can lead to adverse health outcomes. The study highlights the importance of screening strategies for iron deficiency, as it is a common issue that may be overlooked or undertreated.

SourceJAMA Network·JournalJAMA Network Open·DateSep 24, 2024

The RESILIENCE trial: Preventing heart injury caused by anticancer drugs

The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalEuropean Journal of Heart Failure·TypeRandomized controlled/clinical trial·DateSep 13, 2024

Mitral valve repair via catheter offers better outcomes than pharmacological treatment in patients with heart failure

A recent study published in the New England Journal of Medicine demonstrates the benefits of catheter-based mitral valve repair for patients with moderate to severe mitral regurgitation. The procedure showed a significant reduction in recurrent hospitalisations and improved quality of life after 12 months.

SourceGermans Trias i Pujol Research Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateSep 12, 2024

Effects and consequences of cardiac metabolism in the elderly

Research explores relationship between cardiac metabolism dysfunction and heart failure in the elderly, revealing potential therapeutic targets for improved cardiac outcomes. The study highlights the critical role of Pdk4 and MIF in cardiac metabolism, suggesting innovative treatments to manage interconnected cardiovascular conditions.

SourceImpact Journals LLC·JournalAging-US·TypeCommentary/editorial·DateSep 4, 2024

Pregnancy-related heart failure is under-detected; AI-enabled stethoscope helped doctors diagnose twice as many cases

A study at the European Society of Cardiology Congress found that an AI-enabled digital stethoscope helped doctors identify twice as many cases of pregnancy-related heart failure compared to a control group. The tool was 12 times more likely to flag heart pump weakness, leading to better diagnosis and potentially life-saving treatment.

SourceMayo Clinic·JournalNature Medicine·DateSep 3, 2024

Brigham-led clinical trial finds finerenone reduces worsening heart failure and cardiovascular death

A randomized, placebo-controlled trial found finerenone improved outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. The drug also showed benefits regardless of the ejection fraction and even in patients on other approved therapies.

SourceBrigham and Women's Hospital·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateSep 1, 2024

Transcatheter edge-to-edge repair is better than medical therapy alone in patients with heart failure and mitral regurgitation

A randomized controlled trial found that transcatheter edge-to-edge repair (M-TEER) significantly reduced cardiovascular death and hospitalizations for heart failure, compared to medical therapy alone. The study also showed improved health status in patients with moderate to severe functional mitral regurgitation.

SourceEuropean Society of Cardiology·JournalNew England Journal of Medicine·DateAug 31, 2024